1189479-75-1
Chemical Structure
Phenylbutazone-d9
- CAS No.: 1189479-75-1
- Formula:C19H11D9N2O2
- Molecular Weight:317.43
IUPAC Name: 4-(butyl-d9)-1,2-diphenylpyrazolidine-3,5-dione
InChIKey: VYMDGNCVAMGZFE-ABVHXWLASA-N
SMILES: O=C1N(C2=CC=CC=C2)N(C3=CC=CC=C3)C(C1C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O
Biological Activity: Phenylbutazone-d9 is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Phenylbutazone-d9 | Phenylbutazone-d9 is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenylbutazone (Standard) | ≥98% | Phenylbutazone (Standard) is the analytical standard of Phenylbutazone. This product is intended for research and analytical applications. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenylbutazone(diphenyl-d10) | 99.90% | Phenylbutazone(diphenyl-d10) is the deuterium labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenylbutazone-13C12 | 99.90% | Phenylbutazone-13C12 is the 13C12 labeled Phenylbutazone. Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Phenylbutazone | 99.69% | Phenylbutazone is an efficient reducing cofactor for the peroxidase activity of prostaglandin H synthase (PHS). Phenylbutazone, a hepatotoxin, is a nonsteroidal anti-inflammatory agent (NSAID). Phenylbutazone induces muscle blind-like protein 1 (MBNL1) expression and has the potential for ankylosing spondylitis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. G A Reed, et al. Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone. Requirement for peroxidative metabolism. Mol Pharmacol. 1985 Jan;27(1):109-14. [Content Brief]
